2026-10-29

Caterpillar Stock Drops 9% While Eli Lilly Jumps 4% - Same-Day Earnings Beats, Opposite Verdicts on Tariffs vs. Guidance

Written & reviewed by the TradeSmrt editorial team · 2026-10-29

In this article

What Happened
Why Two Beats Split So Sharply
What to Take Away From This
FAQ
Sources

What Happened

On Thursday, October 29, two very different Dow-adjacent companies reported third-quarter earnings on the same morning - heavy equipment maker Caterpillar (NYSE: CAT) and pharmaceutical giant Eli Lilly (NYSE: LLY). Both beat Wall Street's earnings-per-share estimates. Their stocks did not move the same way. Caterpillar fell as much as roughly 9% in premarket trading, while Eli Lilly rose about 4%. Caterpillar had been one of 2026's biggest industrial winners, up more than 50% for the year on an "AI power trade" built around data center electricity demand, while Lilly had just delivered its third full-year guidance raise of 2026 on the strength of its obesity-drug franchise. Looking at why two headline beats landed so differently is a useful lesson in how much the quality of a beat matters - not just its size.

Start with Caterpillar. Adjusted third-quarter earnings per share came in at $7.20, ahead of the roughly $7.03-to-$7.08 analyst consensus - a clear beat on the bottom line. Revenue, however, landed just under the roughly $20.69 billion Wall Street had modeled. CEO Joe Creed talked up strong order rates and a record backlog on the call, but didn't disclose the dollar figure this quarter - a notable omission given that the prior quarter's backlog, at $72.1 billion, was up 92% year over year and had become a key talking point for bulls. More importantly, the earnings beat carried less weight than it looked: the quarter's operating profit included $128 million in tariff recoveries tied to the International Emergency Economic Powers Act (IEEPA), while the company separately absorbed $460 million in unfavorable manufacturing costs, including tariffs. One group of dollars inflated the beat; another group quietly worked against it. On top of that, Caterpillar maintained its full-year revenue growth outlook but said adjusted operating margin would land near the low end of its target range, and it offered no specific fourth-quarter revenue figure. The stock had already fallen about 13% in the month heading into earnings and was still up more than 50% for 2026 - one investor summed it up by noting the stock was "priced for near-perfect results," and this report wasn't quite that.

Caterpillar's 2026 run has been less about a cyclical industrial recovery and more about a re-rating as an AI infrastructure play. As hyperscalers build data centers faster than utilities can expand the grid, Caterpillar's large reciprocating engines and gas turbines have become a go-to source of backup and "prime power" generation. Power Generation segment revenue rose 41% year over year in the first quarter to $2.82 billion, and management has said customers are now locking in orders stretching into 2028 through 2030. Against that backdrop, the absence of an updated backlog number and guidance for margin to sit at the low end of its range were read by some investors as early cracks in the AI-power narrative, even though management didn't frame it that way.

Eli Lilly, by contrast, delivered a textbook clean beat. Third-quarter revenue rose 39% year over year to $24.4 billion, nearly 8% above the roughly $22.61 billion consensus. Adjusted EPS of $7.48 blew past estimates that ranged from $5.60 to $6.26 depending on the data provider. Reported GAAP EPS was lower, at $7.22, reflecting $4.57 per share in one-time charges tied to acquired in-process R&D. The growth engine was obesity and diabetes care: Mounjaro sales rose 65% to $10.7 billion, and Zepbound grew roughly 48-49% to about $5.35 billion - ahead of the $5.09 billion analysts had modeled for Zepbound, per CNBC. The one soft spot was Foundayo, Lilly's oral obesity pill, which brought in $184 million against expectations near $229 million.

Lilly raised its full-year 2026 revenue guidance to $91-92 billion from $85-87 billion - its third guidance increase this year. Adjusted EPS guidance actually ticked down slightly, to $35-36 from $35.50-36.50, but that was purely a function of the $4.57-per-share IPR&D charge; stripped of that charge, the underlying profit outlook actually improved by roughly $4.07 per share at the midpoint. Shares climbed from Tuesday's close of $1,288.30 to as high as $1,344 in premarket trading, a gain of roughly 4-4.6%.

Why Two Beats Split So Sharply

The quality of each beat differed enormously. Caterpillar's EPS beat leaned partly on a one-time tariff recovery, while tariff costs and a margin warning sat right alongside it in the same release - investors dug past the headline and didn't like what they found. Lilly's revenue beat came straight from real product demand, and its EPS, once you back out the acquisition charge, was even stronger than the headline suggested. Second, each stock carried very different expectations into the print: Caterpillar had already priced in a near-flawless AI-power story after a 50%-plus run, leaving little room for ambiguity, while Lilly still faces persistent competitive questions versus Novo Nordisk that a clean beat helped answer. Third, guidance direction mattered more than guidance optics - Caterpillar left open questions (no backlog figure, margin at the low end, no Q4 number) while Lilly's lower EPS guidance came with a fully explainable, one-time cause.

What to Take Away From This

Always decompose an EPS beat before trusting it. Caterpillar's beat included a one-time tariff recovery sitting next to a separate tariff cost headwind. A beat on the headline number doesn't mean the underlying business performance matched it.
Stocks that have already run hard need a flawless quarter. Caterpillar was up more than 50% for the year heading into the print, and even minor gaps - an undisclosed backlog figure, margin guidance at the low end - were enough to trigger a 9% drop.
A lower guidance number isn't always a red flag. Lilly's EPS guidance ticked down on paper, but only because of a one-time R&D charge; the underlying outlook, excluding that charge, actually improved.
Theme stocks get punished for missing details more than fundamentals stocks do. Caterpillar's valuation rests on the AI-power narrative, so the absence of an updated backlog number read as a bigger red flag than it might for a stock without a dominant theme attached.
Same-day earnings reveal completely different exposures. Caterpillar's quarter hinges on tariffs, manufacturing costs, and data center power demand; Lilly's hinges on obesity-drug competition and its drug pipeline. Lumping "earnings season" reports together obscures how differently each company is actually exposed.

FAQ

Why did Caterpillar stock fall when it beat EPS estimates?

Adjusted EPS beat consensus, but the beat was partly inflated by a one-time tariff recovery, while separate tariff-related manufacturing costs and a margin outlook near the low end of guidance offset much of that strength. Combined with the absence of an updated backlog figure, investors read the quarter as lower-quality than the headline number suggested, and an already richly valued stock corrected roughly 9%.

Why did Eli Lilly's stock rise even though EPS guidance was lowered?

The lower EPS guidance was entirely the result of a one-time $4.57-per-share charge tied to acquired R&D. Excluding that charge, the underlying profit outlook actually rose by about $4.07 per share at the midpoint, and revenue guidance was raised for the third time this year. The market focused on the stronger underlying trend rather than the headline EPS number.

Why is Caterpillar considered an "AI power" stock?

Data center construction has outpaced the electric grid's ability to keep up, making Caterpillar's large engines and gas turbines a go-to source of backup and prime power for hyperscalers. Power Generation revenue rose 41% year over year in the first quarter of 2026, and management has described customers locking in orders that stretch into 2028 through 2030.

Are both companies part of the Dow Jones Industrial Average?

Caterpillar is one of the Dow's 30 components. Eli Lilly isn't part of the Dow, but it's one of the largest healthcare names in the S&P 500. With the two stocks moving sharply in opposite directions the same morning, they would have pulled on the Dow and the S&P 500 healthcare sector in opposite ways.

Sources

This article is an original synthesis and analysis based on the reporting below, not a reproduction of the original articles. Please check the source articles directly for the most current figures.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data before making investment decisions.